Stockreport

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion, Inc.  (BMEA) 
PDF New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase [Read more]